The results of the three types of asthma antibody drugs were different. According to the related industry, at the HIRA Pharmaceutical Reimbursement Evaluation Committee held on the 7th, Nucala of GSK Korea was judged to be appropriate for reimbursement, and Fasenra of AstraZeneca Korea was judged to be non-reimbursable.

These drugs are interleukin (IL)-5 antagonists, and only Handok Teva's Cinqair, which uses the same mechanism, passed the Pharmaceutical Review Committee in July and is currently negotiating drug prices with the National Health Insurance Corporation. The reason Singcare was able to get ahead was that it went on the general registration track. On the other hand, difficulties were expecte